Oncology Journal CME/CE

• 11.00 91.00
  Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but Monoallelic del(1p32) Remains a Strong Prognostic Factor
  Blood March 16, 2023
  In the era of risk-adapted treatment strategies, it is crucial to detect del(1p32) at multiple myeloma diagnosis, suggests a cytogenetic study.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Associations of Clonal Hematopoiesis With Recurrent Vascular Events and Death in Patients With Incident Ischemic Stroke
  Blood February 16, 2023
  Identifying genetic/other CH risk factors may improve personalized risk stratification and secondary prevention in ischemic stroke.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Long-Term Risk of Relapse in Immune-Mediated Thrombotic Thrombocytopenic Purpura and the Role of Anti-CD20 Therapy
  Blood January 24, 2023
  Lack of early iTTP relapse or treatment failure predictors mandates regular ADAMTS13 monitoring to prevent progression to clinical relapse.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Outcomes of Patients With Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR T-Cell Therapy: A DESCAR-T Analysis
  Blood December 15, 2022
  Patients with R/R aggressive BCL-failing anti-CD-19 CAR T-cell therapy have an unmet medical need meriting further innovative strategy.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  The Role of Allogeneic Transplant for Adult Ph⁺ ALL in CR1 With Complete Molecular Remission: A Retrospective Analysis
  Blood November 17, 2022
  Adults with Ph⁺ ALL who achieved CMR within 3 months of starting treatment had lower incidence of disease relapse with allo-HCT in CR1.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Incidence and Impact of Anticoagulation-Associated Abnormal Menstrual Bleeding in Women After Venous Thromboembolism
  Blood October 20, 2022
  How prevalent is abnormal uterine bleeding in women with a new venous thromboembolism diagnosis? A new study provides data to help inform clinical decisions.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Role of Allogeneic Transplantation in Chronic Myelomonocytic Leukemia: An International Collaborative Analysis
  Blood September 22, 2022
  In CMML, allogeneic transplantation before transformation cuts life expectancy in lower-risk patients but may be OK for higher-risk patients.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Outcomes Following Treatment for ADA-Deficient Severe Combined Immunodeficiency: A Report From the PIDTC
  Blood August 18, 2022
  In patients with ADA-SCID without infection treated after 2000, hematopoietic cell transplant vs gene therapy showed no survival difference.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 10.25 90.25 20.25 30.25
  Malignant Mesothelioma Mortality in Women — United States, 1999–2020
  Morbidity & Mortality Weekly Report August 16, 2022
  The annual number of deaths with mesothelioma among women significantly increased from 1999 to 2020, warranting continued efforts to limit exposure to asbestos fibers, including among women.
  
  0.25 CME/CEMIN 0.25 ABIM MOCMIN 0.25 CEMIN 0.25 CEMIN

  
  Save
• 11.00 91.00
  Mechanosensation by Endothelial PIEZO1 Is Required for Leukocyte Diapedesis
  Blood July 21, 2022
  Mice with endothelium-specific Piezo1 deficiency had decreased leukocyte extravasation in different models of inflammation, suggesting a novel target that could help regulate pathologic inflammation underlying multiple diseases.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Impact of Diagnostic Genetics on Remission MRD and Transplantation Outcomes in Older Patients With AML
  Blood June 16, 2022
  In older patients with AML, molecular associations with MRD positivity and transplant outcomes are driven primarily by baseline genetics.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 11.00 91.00
  Genomic Landscape of TCRαβ and TCRγδ T-Large Granular Lymphocyte Leukemia
  Blood May 19, 2022
  In LGL leukemia, STAT3 mutations are linked to mutational burden and neutropenia; select STAT3-activating mutations are linked to anemia.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save
• 10.25 90.25 20.25
  Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥ 20 Years — United States, 1999–2018
  Morbidity & Mortality Weekly Report April 22, 2022
  US breast cancer incidence fell 2.1%/y during 1999-2004 and rose 0.3%/y during 2004-2018, particularly in women aged 20 to 39 years who may benefit from discussing ways to reduce risk.
  
  0.25 CME/CEMIN 0.25 ABIM MOCMIN 0.25 CEMIN

  
  Save
• 11.00 91.00
  Inherited Human Apollo Deficiency Causes Severe Bone Marrow Failure and Developmental Defects
  Blood April 21, 2022
  Biallelic Apollo variants cause bone marrow failure clinically similar to DC/HH but with normal telomere length; Apollo is a genome caretaker needed for proper human immuno-hematologic system development.
  
  1.00 CMEMIN 1.00 ABIM MOCMIN

  
  Save